NCT06168461Active, not recruitingEarly phase 1
Daily Aspirin Treatment After Preeclampsia
Aspirin for the Treatment of Vascular Dysfunction After Preeclampsia
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 13 Sept 2023
- Start date
- 1 Nov 2023
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Anna Stanhewicz, PhD
- NCT number
- NCT06168461
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 40
- From 1 Nov 2023 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- statin or other cholesterol-lowering medication,
- current antihypertensive medication,
- history of hypertension prior to pregnancy,
Other illness
- skin diseases,
- history of gestational diabetes,
- allergy to materials used during the experiment.(e.g. latex),
- known allergies to study drugs,
- bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Lab values
- diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2,
Other
- current daily aspirin use,
- current tobacco or nicotine use (including vaping),
- currently pregnancy,
- body mass index \<18.5 kg/m2,
Who the study is looking for
- had preeclampsia in the past 5 years,
- 18 years or older
Age in the registry: 18 years to 50 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Iowa Coordinator of this site? Confirm its status | Iowa City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.